BioSpace News Archive

Total sales for the quarter were $12.8 billion, with its innovative medicines, which include key assets, bringing in $10.8 billion.

As monkeypox continues to spread across the globe, health experts suggest monitoring vaccine effectiveness, population spread and at-risk groups.

Greene LLP announces that the international pharmaceutical company, Biogen, Inc, has agreed to pay $900 million to resolve claims brought by Michael Bawduniak, a client of Greene LLP, that Biogen unlawfully paid kickbacks to physicians and other healthcare professionals.

Enveda Biosciences, a pioneer in small molecule drug discovery using machine learning and metabolomics to harness the potential of natural products, announced that Tobias Kind, Ph.D., will join the company’s industry-leading data science team as Research Fellow.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, August 3rd, at 4:30 p.m. ET to discuss second quarter 2022 financial results and provide a general business update.

Today, Wellspring Ophthalmics, a Mission Viejo-based development stage eye care pharmaceutical company focused on innovating an improved, effective dry eye therapy, announces receiving its second patent for a novel cyclosporine dry eye therapy.

The global dura substitute market was valued at US$ 175.6 Mn in 2022 and is estimated to expand at a CAGR of 5.9% from 2022 to 2030.

Assembly Biosciences, Inc. announced that it is discontinuing further development of its first-generation core inhibitor, vebicorvir, as it prioritizes clinical development of its next-generation core inhibitors, ABI-H3733 and ABI-4334, and advances its research pipeline.

Tabula Rasa HealthCare, Inc. reported preliminary unaudited financial results for the second quarter ended June 30, 2022 and commented on public statements made by Indaba Capital Management, L.P.

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2022 financial results and provide an update on its clinical development programs and regulatory and business outlook on Monday, August 8, 2022, before the open of the US financial markets.